

## Anti-Human CD223 (LAG3) APC

Catalog Number :25311-80

RUO: For Research Use Only. Not for use in diagnostic procedures.

### Product Information

**Clone:** 3DS223H

**Format/Conjugate:** APC

**Concentration:** 5 uL (0.06 ug)/test

**Reactivity:** Human

**Laser:** Red (635 -655nm)

**Peak Emission:** 660nm

**Peak Excitation:** 650nm

**Filter:** 660/20

**Brightness (1=dim,5=brightest):** 5

**Isotype:** Mouse IgG1, kappa

**Formulation:** Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, pH7.2.

**Storage:** Product should be kept at 2-8°C and protected from prolonged exposure to light.

**Applications:** FC

### Description

The 3DS223H monoclonal antibody recognized human CD223, a 70 kDa glycoprotein that is also known as the Lymphocyte Activation Gene 3 (LAG-3). CD223 is an immune checkpoint receptor in the Ig superfamily and its main ligand is MHC class II, which it binds with higher affinity than CD4. It is reported to play a role in Treg suppressive activity and is involved in the maturation and activation of dendritic cells.

### Preparation & Storage

The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

### Application Notes

The antibody has been analyzed for quality through the flow cytometric analysis of the relevant cell type. The antibody can be used at less than or equal to 5 µL per test. A test is the amount of antibody required to stain a cell sample in the final volume of 100 µL.

### References

1. Anvari, S., Grimbergen, A., Davis, C. M., Makedonas, G. (2017). Protein transport inhibitors downregulate the expression of LAG-3 on regulatory T cells. *Journal of immunological methods*, 447, 47-51.
2. Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., ... Liu, Q. (2017). Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma. *Frontiers in immunology*, 7, 690.
3. Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., ... Mackall, C. L. (2016). Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. *Cancer immunology research*, canimm-0230.